New England Journal of Medicine
September 23, 2021 Vol. 385 No. 13
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
List of authors.
Paul T. Heath, F.R.C.P.C.H., et al. for the 2019nCoV-302 Study Group*
A two-dose regimen of the NVX-CoV2373 vaccine administered to adult participants conferred 89.7% protection against SARS-CoV-2 infection and showed high efficacy against the B.1.1.7 variant. (Funded by Novavax; EudraCT number, 2020-004123-16. opens in new tab.)